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Hypoglycemia continues to be a signiﬁcant problem for patients with diabetes. The inci-
dence  remains high but patients may also be under-reporting hypoglycemic events for
various  reasons, including hypoglycemia unawareness and deliberate non-reporting. This
restricts  the ability of healthcare professionals to manage treatment effectively.
The  aim of this article is to focus speciﬁcally on the issues associated with hypoglycemia
unawareness and undisclosed hypoglycemia. The article provides general practice teamseywords:
ypoglycemia unawareness
ndisclosed  hypoglycemia
atient  education
with an overview of these problems and, through patient narratives, suggests ways to mit-
igate  them.
© 2013 Colin Kenny. Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.
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1.  Introduction
In real-life clinical practice, hypoglycemia is a signiﬁcant prob-
lem  for patients with either type 1 or type 2 diabetes. The
incidence remains high and hypoglycemia can often go unrec-
ognized  in primary care. Unfortunately, healthcare providers
are  faced with the dilemma that improving glycemic control
through  intensive diabetes treatment, to reduce the risk of
developing  complications in patients with diabetes, is con-
founded  by the risk of hypoglycemia [1–4]. Hypoglycemia can
have  a signiﬁcant negative impact on patients’ well-being,
daily  routine and lifestyle, preventing them from leading a
fulﬁlling  life, and imposing signiﬁcant burdens on patients as
well as the community [5]. However, patient under-reporting
–  due to hypoglycemia unawareness and possibly deliberate
under-reporting – restricts the ability of healthcare profession-
als  to improve treatment regimens and reﬁne management of
the  disease [6]. The aim of this article is to highlight the issues
associated  with hypoglycemia unawareness and undisclosed
hypoglycemia, the scale of these problems and what can be
done  to mitigate them.
2.  Background  to  hypoglycemia
2.1.  DeﬁnitionCirculating glucose is the primary source of energy for the
brain,  which is therefore vulnerable to low blood glucose
Fig. 1 – Physiological response to hypoglycemia [8]. (Repr. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
levels. In order to protect the brain, a number of physio-
logical mechanisms are activated to minimize the effects
of  hypoglycemia (Fig. 1) [7,8]. The initial response is the
cessation of insulin secretion at a blood glucose thresh-
old  of ∼4.6 mmol/L (∼83 mg/dL) [9]. This is followed by
counter-regulatory hormone responses (starting at 3.8 mmol/L
(68.4  mg/dL)), primarily the release of the fast-acting glucagon
and  epinephrine (adrenaline) hormones, and cognitive and
symptomatic  changes [6,9–11].
In people with type 1 diabetes, an absolute insulin deﬁ-
ciency  precludes the ﬁrst-line defense against falling blood
glucose  levels. In addition, with the loss of the pancreatic -
cell  glucagon secretory response, the last remaining defenses
are  the release of epinephrine and autonomic warning symp-
toms,  which also become attenuated in these patients [12]. In
people with type 2 diabetes, the residual -cell function ini-
tially  preserves the insulin ﬁrst-line defense. However, with
the  progressive loss of -cell function and repeated hypo-
glycemic events, the endogenous glucose counter-regulatory
response is lost [13,14].
The  exact biochemical deﬁnition of hypoglycemia also
varies  between associations, with glycemic thresholds deﬁned
as  follows:
•  European Medicines Agency (EMA), 3.9 mmol/L (70 mg/dL)
[15].oduced with permission of John Wiley & Sons Ltd.).
•  American Diabetes Association (ADA), 3.9 mmol/L
(70 mg/dL) [16].
• Canadian Diabetes Association (CDA), 4.0 mmol/L
(72 mg/dL) [17].
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The recent update to the ADA hypoglycemia guidance has
ot  altered the proposed value, but does state that a single
hreshold value for hypoglycemia cannot be assigned because
he  threshold for physiological responses may  shift up or
own.
The  EMA’s  deﬁnition is a very recent change (originally
.1 mmol/L (56 mg/dL)), which has met  with broad resistance
rom  the medical community in Europe due to the burden it
laces  on people living with diabetes and their carers. This is
ue to the fact that counter-regulatory responses and symp-
oms  are not activated until blood glucose levels fall below
.8  mmol/L (68.4 mg/dL), with the most important cognitive
unctional changes not occurring until levels reach 2.8 mmol/L
50.4  mg/dL) [9]. Thus, the recent change to the EMA’s  hypo-
lycemia  deﬁnition may  lead to a higher number of episodes
eing  recorded that are not a true reﬂection of a hypoglycemic
tate. This will have wide-reaching consequences for the
atient,  especially with regard to permission to drive.
Standard classiﬁcations of hypoglycemia include con-
rmed,  severe and nocturnal hypoglycemic events; these
lassiﬁcations are often used as outcomes in clinical trials
6,16],  although the deﬁnitions used to classify hypoglycemic
vents in clinical trials have varied quite widely. Conﬁrmed
ypoglycemia is an event where a blood glucose measure-
ent  below the deﬁned threshold is available, whilst a severe
vent  is one where the assistance of another person is nec-
ssary.  A nocturnal event is one that occurs during the night,
egardless  of whether the individual is awake or asleep, and
nocturnal’  is generally considered as the period from bedtime
ntil  wake-up [18,19].
.2.  Symptoms
ypoglycemia can cause a variety of symptoms that can
e  classiﬁed as either neurogenic (autonomic) or neuro-
lycopenic (Table 1). Neurogenic symptoms are caused by
hysiological  responses to low glucose concentrations; neu-
oglycopenic  symptoms, due to glucose deprivation in the
entral  nervous system, are more  distressing and severe
6,10,11].
.3.  Frequency
s patients with type 1 diabetes depend on exogenous insulin,
hey  are unable to down-regulate insulin secretion as a ﬁrst-
ine  response, so they experience a higher frequency of
ypoglycemic events than those patients with type 2 diabetes
20].  These hypoglycemic rates are >15-fold lower in orally
reated  and approximately 6-fold lower in insulin-treated
atients with type 2 diabetes than in patients with type 1 dia-
etes  [13]. Interestingly, the frequency of severe hypoglycemia
ncreases over time in patients with type 2 diabetes [21]. The
requencies  of hypoglycemic events reported in some repre-
entative  studies, chosen to include key clinical trials and large
atabase analyses, are listed in Table 2 [1,19–25]. It is worth
oting  that reporting rates may  be lower in clinical practice
han  in trials, where endpoints such as hypoglycemia are care-
ully  monitored. s 8 ( 2 0 1 4 ) 3–11 5
2.4.  Causes  and  risk  factors
Table 3 lists some of the antidiabetic and other drugs that are
most  commonly associated with a risk of hypoglycemia. It is
important to note that, aside from the particular drug used,
dosage  levels are important in determining the risk of hypo-
glycemia,  with higher circulating doses increasing the risk.
Variability  in the glucose-lowering action of insulin ther-
apy  can be a driver for hypoglycemia [26]. Patients can vary
in  the rate at which they absorb injected insulin (inter-patient
variability) and even variations in the absorption proﬁle can
occur  from day to day within the same patient (intra-patient
variability) [26]. Modern basal insulin analogs have been for-
mulated  to reduce this variability, thus lowering the risk of
hypoglycemia compared with human insulin or neutral pro-
tamine  Hagedorn (NPH) insulin, although there is still room
for  further improvement [26].
In addition to antidiabetic treatment, there are other
causes of hypoglycemia including inadequate, delayed or
missed  meals; exercise; hot weather; the use of recreational
drugs or excessive alcohol consumption; and age-related
impairment of the counter-regulatory hormone responses
[9,11,27]. More long-term factors that can inﬂuence the risk
include  change in weight, renal or liver dysfunction and
concomitant medications [12,28,29]. In addition, depression,
which  many  people with diabetes suffer from, has been found
to  be associated with the risk of severe hypoglycemia [30].
Box: Hypothetical case study 1: An elderly patient with
a  high risk of hypoglycemia
Jean  is an 84-year-old widow who has had type 2 diabetes
for  16 years. She lives in a warden-controlled dwelling
and has her medication prepared in a ‘dosette’ box each
week.  She is currently taking sustained-release met-
formin 1 g daily and gliclazide 160 mg  twice daily, as well
as  a statin drug and two anti-hypertensive agents.
She attends a diabetes review where she states that she
is  well, although her diet seems to be restricted, but she
states  that she has no symptoms. You note she had a fall
3  months previously and fractured her wrist. Her current
HbA1c is 6.4% (46 mmol/mol), which has been reduced
over the past year.
You  are concerned that Jean is a vulnerable adult as she
lives  on her own with minimal supervision and her eat-
ing  habits may  be erratic. You note that she has a low
HbA1c. Her sulfonylurea medication and erratic eating
habits leave her vulnerable to hypoglycemia, which may
go  under-recognized.
You decide to stop the gliclazide as you feel that her cur-
rent  diabetes control is too tight to be safe. You check
her renal function to ensure that she can use metformin
safely. You adjust her ‘dosette’ box with the dispensing
chemist and ensure that she has a suitable diet, and has
meals  provided as appropriate.Sulfonylureas can also cause hypoglycemia related to abso-
lute/relative insulin excess and may  pose the greatest risk of
hypoglycemia  to patients with renal or hepatic dysfunction
6  p r i m a r y c a r e d i a b e t 
Table 1 – Symptoms of hypoglycemia [6,10,11].
Classiﬁcation Typical symptoms
Neurogenic Trembling, sweating, anxiety, hunger
Neuroglycopenic Cognitive impairment, confusion, behavioral
of  another person) occurs within 12 months or the individ-changes
Loss of consciousness (even death) in severe
cases
and to elderly adults [9]. Sulfonylurea-induced severe hypo-
glycemia  can be long-lasting, requiring hospitalization and
long-term  glucose infusion [9]. The risk of hypoglycemia
is related to the pharmacokinetic properties of the drug.
Therefore, the longer-acting sulfonylureas are associated
with  a greater risk compared with their shorter-acting coun-
terparts  and should be avoided in contemporary primary care
[9].
As  patients will vary in their exposure and susceptibility to
the  different triggers of hypoglycemia, it is essential for the
physician  to constantly reﬁne the treatment strategy for each
patient,  using an individualized approach to achieve glycemic
targets.
3.  Hypoglycemia  unawareness  and
undisclosed  hypoglycemia:  the  scale  of  the
problem and  the  consequences
3.1.  Hypoglycemia  unawareness
3.1.1.  Deﬁnition
Hypoglycemia unawareness (also called ‘impaired awareness
of  hypoglycemia’) is deﬁned as the onset of hypoglycemia
before the appearance of autonomic warning symptoms, and
presents  clinically as the patient’s inability to perceive hypo-
glycemic  symptoms [13,31,32].
As noted above, when glucagon responses to hypo-
glycemia become deﬁcient, epinephrine and autonomic
warning symptoms develop into the critical defenses for
glucose  counter-regulation. However, repeated hypoglycemic
events  (including those that are non-severe, asymptomatic
or  nocturnal) can reduce the magnitude of these responses
to  subsequent hypoglycemic episodes. Consequently, the
counter-response is initiated at increasingly lower glucose
concentrations and the perception of hypoglycemia becomes
impaired,  all resulting in an increased risk of future hypo-
glycemic events, particularly severe events [13,33,34].
Aside from repeated hypoglycemic events, other risk fac-
tors  for the impairment of hypoglycemia awareness include
physiological (e.g. overly strict glycemic control), psychologi-
cal  (e.g. denial) and educational factors (e.g. little knowledge
about  treatments), and concomitant drugs (e.g. unselective
-blockers due to changes to sympatho-adrenal stimulation)
[31,32].
3.1.2.  Frequency
The incidence of hypoglycemia unawareness has been inves-
tigated  in a number of studies. Overall, a higher proportion
of  patients with type 1 diabetes are reported with hypo-
glycemia unawareness compared with patients with type 2
diabetes. One study determined that 25% of patients withe s 8 ( 2 0 1 4 ) 3–11
type 1 diabetes had “partial” or “absent” awareness [35],
while another found that 19.5% of patients in secondary care
had  hypoglycemia unawareness [36]. Among insulin-treated
patients with type 2 diabetes, 9.8% had trouble correctly
identifying hypoglycemic events [37].
As the counter-response is initiated at lower glucose con-
centrations, the risk of severe hypoglycemic events increases
markedly  in patients with hypoglycemia unawareness [38].
Schopman et al. showed that those patients with type 2 dia-
betes  and hypoglycemia unawareness had a 17-fold higher
incidence of severe hypoglycemic events than patients with
normal  awareness [37]. Severe hypoglycemic events are sub-
sequently  associated with an increased risk of morbidity and
mortality,  further emphasizing the need to minimize hypo-
glycemia  [31].
Box: Hypothetical case study 2: A patient with hypo-
glycemia unawareness
Jane  is a 27-year-old married schoolteacher who  has had
type  1 diabetes for 8 years. She is currently controlled
on a basal–bolus insulin regimen. She does carbohydrate
counting, having successfully completed a Dose Adjust-
ment  For Normal Eating (DAFNE) course 6 months ago.
She  attends the clinic, stating that her husband has
noticed that on two or three nights during the week
she has woken up sweating and uncomfortable. On fur-
ther  questioning you discover that she has increased her
exercise  regime to include one aerobics class and two
spinning classes per week.
You  feel that she may  have undiscovered night-time
hypoglycemia. You encourage her to monitor her blood
sugars  before and after exercise. She should not engage
in  heavy physical activity if sugars are either too high or
too  low. She will want to take appropriate carbohydrate
after exercise. In the short term, she may  want to wake
between 2 and 3 am to do glucose monitoring.
3.2.  Undisclosed  hypoglycemia
The extent of under-reported and undisclosed hypoglycemia
is  quite difﬁcult to ascertain. There are observational reports
indicating  that some patients do not discuss hypoglycemia
with their physicians for a number of reasons, including feel-
ings  that hypoglycemia is a private issue that they do not
feel  comfortable sharing with others [39,40]. Patients may  also
not understand the importance of hypoglycemia (especially
non-severe episodes) or they may  be concerned about losing
their  driving license or job if they report a serious or frequent
event(s)  [11].
Indeed,  in the UK, a recent update to the Driver and Vehi-
cle  Licensing Agency (DVLA) rules indicates that if more  than
one  episode of severe hypoglycemia (requiring the assistanceual  develops impaired hypoglycemia awareness, this needs to
be reported and could lead to revocation of the individual’s
license [41,42].
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Table 2 – Incidence and prevalence of hypoglycemia in insulin-treated patients from selected clinical trials and analyses [1,19–25].
T1D Design N All hypoglycemia Severe hypoglycemia
Incidence (episodes/PYE) Prevalence (%) Incidence  (episodes/PYE) Prevalence (%)
DCCT [19] 1991 Prospective randomized 817 NA NA 0.19 (standard) 8.6
0.62 (intensive) 17.9
Donnelly et al. [20] 2005 Prospective 94  42.89 82.0 1.15 4.0
Leiter et al. [22] 2005 Retrospective 202 102.0 95.5 2.6 27.2
UK Hypo Study Groupa [21] 2007 Retrospective <2  years: 46 35.5 NA 1.1 NA
>5 years: 54 29.0 NA 3.2 NA
T2D Design N All hypoglycemia Severe hypoglycemia
Incidence (episodes/PYE) Prevalence (%) Incidence (episodes/PYE) Prevalence (%)
VA CSDM [23] 1995 Prospective randomized 153 1.5  (standard) 56.0 (standard) 0.01 (standard) NA
16.5 (intensive) 93.0 (intensive) 0.03 (intensive) NA
UKPDS [1] 1998 Prospective randomized 3935 NA 36.5 NA 2.3
Miller et al. [24] 2001 Retrospective 1055 NA 30.5 NA 0.5
Henderson et al. [25] 2003 Retrospective 215 NA 73.0 0.28 15.0
Donnelly et al. [20] 2005 Prospective 173 16.36 45.0 0.35 3.0
Leiter et al. [22] 2005 Retrospective 133 66.0 72.9 5.9 14.3
UK Hypo Study Groupa [21] 2007 Retrospective <2  years: 85 4.08 NA 0.1 NA
>5 years: 75 10.2 NA 0.7 NA
a Patients were classiﬁed by duration of their diabetes. NA: not applicable; PYE: patient-year of exposure; T1D: type 1 diabetes; T2D: type 2 diabetes.
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Table 3 – Drugs (antidiabetic and others) that are or are not associated with a risk of hypoglycemia.
Associated with a risk of hypoglycemia
OADs  Sulfonylureas, meglitinides (nateglinide, repaglinide), glimepiride
Insulin All insulins
Other  drugs Alcohol, aspirin, warfarin, allopurinol or probenecid when in combination with antidiabetic
medications
Not  usually associated with a risk of hypoglycemia on their own
OADs Alpha-glucosidase inhibitors, biguanides (metformin), thiazolidinediones, GLP-1 agonists, DPP-4
inhibitors, SGLT2 inhibitors
DPP-4 inhibitors: dipeptidyl peptidase-4 inhibitors; GLP-1: glucagon-like pe
transporter 2
Box: Hypothetical case study 3: A patient with undis-
closed hypoglycemia
Robert is a 43-year-old taxi driver who holds a public
service vehicle license. He has had type 2 diabetes for 14
years  and has been using insulin for 3 years. He attends
an  examination to renew his license. He is on twice-daily
pre-mixed insulin as well as metformin. His last recorded
HbA1c was  8.8% (73 mmol/mol) 10 months ago. You note
that  he is currently driving long hours and at night. He
has  not brought his diary with him, and has missed two
recent  diabetic appointments.
You  are concerned that you have very little evidence on
which  to assess how safe Robert is driving as he admits to
neither  hypoglycemic episodes nor daytime sleepiness.
You  take a detailed dietary history, provide him with a
meter  with a memory,  examine his injection technique
and advise him of his obligations to maintain satisfac-
tory control. You give him a printout of the Driver and
Vehicle Licensing Agency (DVLA) guidance or make sure
he  has an internet link to it, if he prefers. You record in
his  clinical record what has been done. The license form
is  not ﬁlled out until better objective evidence of safety
is  obtained.
feels  comfortable sharing with their physician what can be a
very personal experience. It can also help to remove any feel-4.  Methods  to  mitigate  the  problem
Improving patient education and empowering the patient to
take some control over their disease are often very valu-
able  tactics to improve both treatment outcomes [43,44] and
treatment  adherence, and therefore reduce the frequency of
hypoglycemia  [45–47]. If the doctor can help the patient to
clearly  understand how their antidiabetic drugs and/or insulin
work  and impact their glucose levels in relation to their every-
day  activities, this will go a long way  toward improving overall
patient  care [6,28,40,48,49].
“Patient empowerment” is an approach that emphasizes
collaboration with patients in helping them to understand
their disease, develop personal goals to manage it, and adapt
their  management as needed according to circumstances [45].
Shared decision making and a collaborative approach to goal
setting  are central to empowerment [45]; the focus is on
increasing the patient’s autonomy rather than on obtaining
increased compliance with the instructions of those in author-
ity  [50].ptide 1; OADs: oral antidiabetic drugs; SGLT2: sodium–glucose linked
4.1.  Hypoglycemia  unawareness:  diagnosis  and
patient education
Doctors can help their patients to identify hypoglycemia
unawareness by taking a full clinical history, using a struc-
tured  questionnaire to assess past hypoglycemia experiences,
and  recommending increased self-monitoring of blood glu-
cose  (see Section 4.3 “Use of technology” below). In addition,
a  Likert scale is available that allows patients to score
their own awareness on a scale from 1 to 7, where a low
score  represents normal awareness and a high score des-
ignates  loss of awareness [31,51]. This self-reported failure
to  perceive hypoglycemic symptoms via a questionnaire
setting has been shown to be extremely accurate when com-
pared  with a quantitative blood glucose symptom/estimation
trial [52,53], with hypoglycemia unawareness associated
with a 9-fold higher risk of severe hypoglycemic events
[25].
It  is important for healthcare providers to be aware of
the  possibility that their patients may  be experiencing hypo-
glycemia  unawareness, as early recognition may  help to slow
or  even arrest its progression if the necessary steps are taken
to  minimize the occurrence of hypoglycemic events [31]. A
valuable  source of information is to interview spouses and
family  members, as they often recognize hypoglycemic events
before  the patient with hypoglycemia unawareness perceives
them.
Therefore, the primary objective should be to avoid all
hypoglycemic events as much  as possible. Table 4 contains
some  useful treatment strategies that can be used to mini-
mize  the occurrence of hypoglycemia. Changing the type of
treatment  or the regimen to one that has shown a lower risk
of  associated hypoglycemia may  also help to reduce hypo-
glycemic  events; however, this does need to be combined with
additional  patient education to ensure that improvements
from the switch are maximized.
4.2.  Undisclosed  hypoglycemia
As an initial step, it is vital for healthcare professionals to ask
their  patients about their hypoglycemic experiences in terms
of  frequency, severity, and the emotional impact these events
may  be having on the patient [39,40]. This can help to build a
personal  relationship and a level of trust, such that the patienting  that they need to hide what they may  consider a personal
failure.  Practicing patient empowerment, as described above,
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Table 4 – Practical treatment strategies for patients with hypoglycemia unawareness [16]. (Reproduced with permission
from American Diabetes Association).
Blood glucose monitoring
Frequent blood glucose monitoring, especially before meals, at bedtime and during suggestive symptoms
Avoid low blood glucose values
Evaluate blood glucose targets
Insulin
Adjust insulin regimen to achieve and maintain target glucose levels
Consider using basal insulin analogs to decrease the risk of nocturnal hypoglycemia
Consider using carefully adjusted, rapid-acting insulin analogs to decrease the risk of interprandial
hypoglycemia
Consider a CSII pump or CGM device as appropriate
Diet
Ensure adequate caloric intake with interprandial and bedtime snacks, as required, strictly based on blood
glucose measurements
Ensure  blood glucose measurements are taken before, during and after exercise
Pre-exercise – additional caloric intake if blood glucose values indicate falling glucose levels
Ensure  access to readily absorbable carbohydrates when embarking on exercise
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CGM: continuous glucose monitoring; CSII: continuous subcutaneous
ay  encourage a more  open relationship between doctor and
atient.
Case  study 3 highlights the ethical dilemma faced by physi-
ians.  On the one hand they wish to do beneﬁcence and be
he  patient’s advocate; on the other hand, they must also act
ithin  a framework of social justice and perform their duty to
ublic safety by ensuring safety for other road users. If doctors
ave  suspicions about driver safety, they should encourage
atient disclosure and, as a last resort, inform the DVLA them-
elves,  having informed the patient accordingly.
.3.  Use  of  technology  to  improve  management  of
ypoglycemia
ontinuous glucose monitoring (CGM) is a useful system
hat  may  help individuals to detect nocturnal or otherwise
symptomatic hypoglycemia [54]. Originally, CGM technology
llowed  the analysis of glycemic proﬁles or highlighted cer-
ain  trends or patterns. However, with technology continually
eing  improved, these systems are now beginning to provide
eal-time  data and alerts for the individual.
It is important to bear in mind that although the accuracy
f  these systems is constantly being improved, there is still
 high level of inaccuracy, random sources of noise that can
lter  readings, and delays between actual glucose levels and
eadings  [54]. There is also a tendency to inaccurately estimate
he  time spent under hypoglycemic conditions [55,56].
Despite these issues, these systems can be useful to both
he  patient and the physician, not only by providing an early
arning  system for both hyper- and hypoglycemia, but also by
roviding long-term data that may  reveal particular patterns
ontributing to recurring and/or asymptomatic hypoglycemic
pisodes.
In  addition to CGM, there are also continuing improve-
ents in glucose monitors. Many  companies are advancing
heir  technology to allow blood glucose readings to be shared
ith  physicians in real time. This is primarily via a mobile
hone  connection, with the blood glucose data being uploaded
o  a secure webpage where physicians can access it and
rovide  advice and messages to the patient directly. This inter-
ction  helps to create a strong connection between physicianlin infusion.
and patient, and also allows for useful analyses of the data
over  the long term. In particular, the technology can provide
information to users and physicians on glucose variability. If
patterns of variability can be identiﬁed, steps can be taken to
address  the root cause (e.g. possibly incorrect dosing, erratic
routines).
Electronic  records of glucose monitoring are very important
for  people with type 1 diabetes in the UK who want to drive
because  such records provide important evidence to DVLA
medical  ofﬁcials in terms of a person’s safety to drive. People
with  type 1 diabetes who want to obtain a Class 2 vocational
driving license will require such an electronic record as evi-
dence  of freedom from hypoglycemic episodes over a 6-month
period.
Healthcare  professionals may  therefore need to whole-
heartedly embrace the use of the internet and technology in
order  to provide the best possible care for their patients.
5.  Summary
Hypoglycemia is an important and under-recognized aspect
of  both type 1 and type 2 diabetes treatment and represents
a  signiﬁcant barrier to improving diabetes care for patients
on  multiple levels. Healthcare providers, as much  as possi-
ble,  need to be aware of under-reporting or under-recognized
hypoglycemic events to ensure the best possible outcome for
their patients.
Improving patient education, empowering the patient,
modifying treatment (bearing in mind variability of drug
effect),  and incorporating the latest technological advances
may  all help to reduce the frequency of hypoglycemic
episodes, minimize the progression toward impaired aware-
ness,  and improve overall patient care.
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